Cargando…
Rabies immunoglobulin should not be forgotten in category III exposure
Autor principal: | Gozdas, Hasan Tahsin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Medicina Tropical - SBMT
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687497/ https://www.ncbi.nlm.nih.gov/pubmed/34932766 http://dx.doi.org/10.1590/0037-8682-0470-2021 |
Ejemplares similares
-
Persistent mental symptoms and rabies
por: GOZDAS, Hasan Tahsin, et al.
Publicado: (2015) -
Safety and clinical efficacy of human rabies immunoglobulin in post exposure prophylaxis for category III animal exposures
por: Haradanhalli, Ravish S., et al.
Publicado: (2022) -
Should pyrazinamide be preferred in tuberculosis treatment during pregnancy?
por: Karabay, Oguz, et al.
Publicado: (2013) -
Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure
por: Kang, Gagandeep, et al.
Publicado: (2023) -
Time to Revise the WHO Categories for Severe Rabies Virus Exposures–Category IV?
por: Scholand, Stephen J., et al.
Publicado: (2022)